Improving R&D productivity of pharmaceutical companies through public–private partnership: experiences from the Innovative Medicines Initiative

Click to increase image sizeClick to decrease image size

Disclaimer

The opinions expressed in this article do not necessarily reflect the positions and opinions of the European Commission or the European Federation of Pharmaceutical Industries and Associations.

Financial & competing interests disclosure

The authors are employees of the Innovative Medicines Initiative co-funded by the European Commission and the European Federation of Pharmaceutical Industries and Associations. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.